Kraig Labs Gains Spotlight as Biotech Consolidation Accelerates
Event summary
- Kraig Biocraft Laboratories' recombinant spider silk technology featured on the cover of National Geographic's March 2026 issue.
- Gilead Sciences acquires Arcellx for $7.8 billion, gaining control of anitocabtagene autoleucel, a BCMA-directed CAR T-cell therapy.
- ImmunityBio reports 700% revenue growth for ANKTIVA, expanding regulatory authorization to 33 countries.
- Getty Images and Shutterstock receive unconditional antitrust clearance from the U.S. DOJ for their proposed merger.
The big picture
The biotech sector continues to see significant consolidation, with Gilead's acquisition of Arcellx highlighting the premium placed on validated cell therapy platforms. Meanwhile, Kraig Labs' feature in National Geographic underscores the growing interest in innovative materials science. In media, the Getty Images-Shutterstock merger signals a push for scale in the visual content and generative AI landscape. These developments reflect broader trends of capital flowing toward platforms with scientific validation and regulatory traction.
What we're watching
- Commercial Scaling
- Whether Kraig Labs can deliver on its projected commercial output and secure long-term partnerships in luxury fashion and performance sportswear.
- Regulatory Approval
- The FDA's decision on anitocabtagene autoleucel, with a PDUFA action date of December 23, 2026, and its potential impact on Gilead's oncology portfolio.
- Market Positioning
- The pace at which ImmunityBio can expand ANKTIVA's regulatory footprint and establish it as a backbone immunotherapy platform.
Related topics